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Diagnostic Dilemmas
A 50-year-old man with cerebral palsy, intellectual im
epilepsy was referred to hospital with a 1-week hi
chills, rigors, haematuria and loin pain. His usua
included phenytoin 300 mg/day, phenobarbitone 3
carbamazepine 1200 mg/day. There was no history 
disease.A 50-year-old man was transferred to the intensive care unit with high anion gap metabolic acidosis. 
Investigations suggested a diagnosis of pyroglutamic acidaemia. Factors contributing to the acidosis 
were medications (paracetamol and flucloxacillin), sepsis and renal failure. The acidosis resolved 
with supportive therapy and withdrawal of the drugs. It is important to recognise this treatable 






At hospital admission (Day 1), he was conscious, in no obvious
distress, and afebrile. He was dehydrated and tachypnoeic (respi-
ratory rate, 22 breaths/minute), but haemodynamically stable.
There was no pallor, jaundice or cyanosis. Cardiorespiratory
examination was unremarkable. Abdominal examination revealed
tenderness in the left renal angle, left loin and right upper
quadrant with no features of peritonism.
Key initial (and subsequent) screening investigations are sum-
marised in Box 1. Of note was neutrophilia and significant renal
impairment (glomerular filtration rate, 28 mL/min by MDRD
4-variable equation). Urinalysis showed sterile pyuria, haematu-
ria (dysmorphic red blood cells on microscopy) and proteinuria
(3.46 g following 24-hour collection). A chest x-ray (CXR)
showed mild generalised bronchial wall thickening, with no focal
parenchymal opacity. Treatment with empirical broad-spectrum
intravenous antibiotics (ceftriaxone and gentamicin) was initi-
ated for suspected urinary tract infection following blood and
urine cultures.
A computed tomography (CT) scan on Day 1 revealed a 2.3 cm
simple cyst in the upper pole of the right kidney, multiple nodules
in the lung bases and a small left pleural effusion. A vasculitic
work-up, including assessment of antinuclear antibody, extractable
nuclear antigen, antibodies to double-stranded DNA, antineu-
trophil cytoplasmic antibodies and complement levels, did not
assist in diagnosis. Urine culture was negative, so a renal biopsy
was performed to establish the aetiology of the acute nephritic
syndrome, consistent with IgA nephropathy with mild activity
(segmental crescents/necrotising lesions in two of 14 glomeruli),
but without scarring. No treatment was indicated.
In view of the persistent fever on Day 3, a repeat CXR was
performed. A small left-sided effusion was noted and pleural fluid
aspirate was consistent with an exudate (pleural fluid white cell
count [WCC], 16.6   109/L; 85% neutrophils; total protein, 37 g/L;
lactate dehydrogenase [LDH], 420 U/L), which was presumed
secondary to an underlying pneumonic process. Intravenous
flucloxacillin was commenced at 2 g/day to broaden the gram-
positive antibiotic cover and continued for 11 days. Blood, urine
and pleural fluid cultures were negative.
Despite initial clinical and laboratory improvement, the fever














Haemoglobin (g/L) 125 115 120 135–175
White cell count (  109/L) 13.6 24.7 7.82 4–11
Neutrophil count (  109/L) 11.1 22.75 6.09 1.8–7.5
International normalised 
ratio
1.2 7.6 1.0 0.8–1.2
APTT (s) 27 65 26 24–37
Fibrinogen level — 5.7 — 1.5–4.0
D-dimer FDP — 2.15 — < 2.0
Biochemistry
Sodium (mmol/L) 134 138 137 137–145
Potassium (mmol/L) 3.9 2.8 4.1 3.5–4.9
Chloride (mmol/L) 97 93 99 100–109
Bicarbonate (mmol/L) 23 6 29 22–32
Urea (mmol/L) 9.1 18.6 2.7 2.7–8.0
Creatinine (mmol/L) 0.210 0.541 0.100 0.05–0.12
Gamma GT (U/L) 152 92 116 0–60
Albumin (g/L) 25 17 23 34–48
Lactate dehydrogenase (U/L) 252 293 210 110–230
Serum amylase (U/L) — 119 — 20–100
C-reactive protein (mg/L) 290 160 47 < 10
Anion gap (mmol/L) 18 42 13 7–17
Lactate level (mmol/L) — 0.7 — 0.2–2.0
Serum pyroglutamic acid 
level† (μmol/L)
— 11 010 — 15–215
Urine pyroglutamic acid 
level† (μmol/mmol 
creatinine)
— 20 495 13 103 < 100
* Platelet count, bilirubin, alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase and creatinine kinase were normal when measured.
† Initial serum and urine pyroglutamic acid levels were measured 36 hours after 
admission  to the intensive care unit, and repeat urine test was performed on 
Day 10. Serum and urine pyroglutamic acid levels not measured at discharge. 
— = Not measured. Bold indicates highly abnormal results.
APTT = activated partial thromboplastin time.
FDP = fibrinogen degradation products. 
GT = glutamyl transpeptidase. ICU = intensive care unit. ◆MJA • Volume 185 Number 4 • 21 August 2006 223
D IAG NOSTIC DILEMMA Spleural effusion size. Repeat pleural aspirate confirmed an
empyema (pleural fluid pH 6.4; LDH, 833U/L; glucose, 0.2mmol/L)
requiring intercostal catheter insertion. However, there was mini-
mal further drainage, despite intrapleural streptokinase adminis-
tration.
On Day 14, ceftriaxone and gentamicin were changed to
empirical timentin and ciprofloxacin because of persistent fever and
rising WCC. Flucloxacillin was increased to 4 g/day. Oral paracet-
amol (1 g every 6 hours as required) and subcutaneous fentanyl
were administered for pain relief. On Day 18, deteriorating renal
function and conscious state necessitated transfer to the intensive
care unit (ICU).
Investigations at ICU admission (Box 1) revealed a severe high
anion gap (42 mmol/L) metabolic acidosis. Arterial blood gas
analysis (on 100% inspired oxygen) showed a pH of 7.31, PaO2
242 mmHg, PaCO2 12 mmHg, and HCO3 5.6 mmol/L. Flucloxa-
cillin and paracetamol were ceased, and intravenous vancomycin
was commenced. Intravenous bicarbonate infusion (25 mL/hour),
commenced in the ward for the acidosis, was continued. With
supportive therapy (fluids, oxygen, antibiotics), the patient
improved over the next 36 hours and the metabolic acidosis
resolved.
Following stabilisation, the patient underwent decortication of
the left pleura. Histopathology was consistent with an organising
fibrinous pleuritis. No bacteria were seen. Decortication was
complicated by significant bleeding, requiring massive transfusion.
After surgery, the patient’s renal function, respiratory function and
conscious state steadily improved; he was extubated 5 days after
decortication. Recovery was complicated by protracted vomiting.
Endoscopy confirmed a Barrett’s oesophagus and small hiatus
hernia; he improved with a proton-pump inhibitor. In the absence
of further respiratory compromise, he was discharged home.
Diagnosis
The cause of the high anion gap metabolic acidosis at ICU
admission was not immediately apparent. Serial evaluation of
biochemical markers showed worsening renal function. However,
even with a creatinine level of 0.541 mmol/L, the expected level of
unmeasured anions was only 10–19 mmol/L and was insufficient
to explain an anion gap of 42 mmol/L and the severity of the
metabolic acidosis. Lactate (0.7 mmol/L) and blood glucose levels
(6.1 mmol/L) were not elevated, and urinalysis was negative for
ketones, suggesting that lactic or keto-acidosis were unlikely
causes (blood ketones were not measured). There was no history
of salicylate administration or ethylene glycol, ethanol or methyl
alcohol consumption.
Case-note review indicated that the patient had received a total
of 8 g of paracetamol and 16 g of flucloxacillin in the 4 days before
ICU admission. Ongoing sepsis and worsening renal failure, in
combination with these drugs, suggested a possible diagnosis of
pyroglutamic acidaemia (PGA).
Urine pyroglutamic acid levels, highly elevated 36 hours after
ICU admission (Box 1) remained elevated 10 days later, although
the values had decreased significantly. Plasma pyroglutamic acid
levels were also markedly elevated 36 hours after ICU admission
(Box 1). The very high urine and plasma pyroglutamic acid levels
supported our diagnosis of PGA. Red cell glutathione synthetase
activity was normal (5.6 μmol/g haemoglobin; reference range,
4.2–9.8 μmol/g haemoglobin), suggesting that it was unlikely that
this patient had a hereditary disorder of the γ −glutamyl cycle.
Discussion
High anion gap metabolic acidosis is frequently encountered in
critical care practice. Recently, there have been several reports of
high anion gap acidosis resulting from excess production of 5-
oxoproline, and termed “pyroglutamic acidaemia”.1-5 This acidae-
mia is most frequently reported with paracetamol therapy,1 but has
also been associated with flucloxacillin2 and vigabatrin,3 particu-
larly in the setting of severe sepsis, renal or hepatic dysfunction.4
The reported inciting dose of paracetamol has been variable: 8 g
of paracetamol daily for 3 weeks in one study,6 and a cumulative
dose of 20.8 g of paracetamol over 2 weeks in another.7 In a series
of 11 patients with transient oxoprolinuria, all patients were taking
paracetamol, with most receiving therapeutic dosages.8 A serum
paracetamol level of > 200 μmol/L was seen in only one of the eight
patients in whom paracetamol levels were checked. Our patient
2 The γ -glutamyl cycle: mechanism of oxoprolinuria
Sepsis and paracetamol reduce glutathione levels, lifting feedback inhibition of γ -glutamyl cysteine synthetase. Excess γ -glutamyl cysteine is converted by γ -glutamyl 
cyclotransferase to 5-oxoproline, the build-up of which leads to acidaemia and oxoprolinuria. Flucloxacillin may inhibit further the rate-limiting enzyme 5-oxoprolinase. ◆
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D IAG NOSTIC DILEMMA Sreceived a cumulative dose of 8 g of paracetamol over 4 days, and
it is likely that PGA was precipitated by a combination of factors,
including sepsis, renal dysfunction, and co-administration of
flucloxacillin.
PGA also occurs with genetic deficiency of either glutathione
synthetase or 5-oxoprolinase.5 However, not all causes of
5-oxoprolinuria are necessarily associated with acidaemia.
The mechanism of non-hereditary PGA is probably multifact-
orial. Suppression of glutathione levels because of sepsis, as seen in
animal models of polymicrobial sepsis,9 may have contributed to
the development of PGA in our patient. Flucloxacillin could have
further compounded this acidosis by inhibiting the breakdown of
pyroglutamic acid by 5-oxoprolinase.2 The role of paracetamol in
PGA is more complex.
The metabolite of paracetamol, N-acetyl benzoquinoneimine,
reacts irreversibly with glutathione. Under normal circumstances,
glutathione depletion leads to increased γ -glutamyl cysteine syn-
thetase activity and excessive production of γ -glutamyl cysteine
(Box 2). However, under altered conditions, glutathione syn-
thetase activity becomes rate-limiting, leading to the conversion of
γ -glutamyl cysteine to 5-oxoproline by γ -glutamyl cyclotrans-
ferase.5 Our patient’s antiepileptic medications, which are known
hepatic enzyme inducers and metabolised via CYP2E1, may have
further compromised glutathione availability by decreasing glu-
tathione stores and competing with paracetamol for metabolism.
Renal impairment may also be important. Renal tubular epithe-
lial dysfunction may impair intracellular glutathione re-formation
(a high ATP-requiring state), leading to accumulation of 5-oxopro-
line and prompt excretion (because of its small molecular size) into
the urine, peritubular capillaries and systemic circulation.
The use of N-acetyl cysteine to treat PGA has been advocated to
replenish glutathione stores by supplying cysteine for glutathione
synthesis. Another theoretical treatment option is the use of
cysteamine, which increases cytosolic cysteine and restores sub-
strate availability for the glutamate pathway, normalising pyro-
glutamic acid levels.
As PGA can be easily missed in a critically ill patient, where
several factors may contribute to a metabolic acidosis, a high index
of suspicion is required to diagnose this condition. PGA should be
considered in the differential diagnosis of high anion gap acidosis,
especially when the levels of organic acids do not sufficiently
account for the degree of anion gap and when there is co-
administration of drugs such as paracetamol and flucloxacillin.
Where PGA is suspected, the offending drugs should be with-
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